Merrimack Pharmaceuticals, Inc. (MACK)
NASDAQ
Healthcare
Biotechnology
$15.14
▲ +0.10%
Market Cap
$224.0M
Sector
Healthcare
Industry
Biotechnology
Beta
1.42
52-Wk Range
11.53-15.89
CEO
Gary L. Crocker
Country
US
Currency
USD
Merrimack Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Cambridge, MA, US. The stock last traded at $15.14, up 0.10% on the session, giving a market capitalisation of $224.0M. On trailing twelve-month figures it carries a trailing P/E of -183.35, a net margin of 0.0%. Its beta of 1.42 implies it has historically moved more than the broad market.
Valuation & profitability (TTM)
P/E
-183.35
Price / Sales
0.00
Price / Book
11.55
EV / EBITDA
216.47
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.00
Current ratio
43.50
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
0
IPO date
2012-03-29
Headquarters
Cambridge, MA, US
About Merrimack Pharmaceuticals, Inc.
Founded in 1993, Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts.
Comparable companies
Merrimack Pharmaceuticals, Inc. is most often compared with the following Healthcare names:
More research on MACK
Open full interactive analysis & DCF →